Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan

Eiji Nakata,Tatsunori Osone,Toru Ogawa,Tomoyuki Taguchi,Kana Hattori,Shinji Kohsaka

DOI: https://doi.org/10.1002/cam4.7351

IF: 4.711

2024-06-26

Cancer Medicine

Abstract:In the C‐CAT database NTRK gene fusions were identified in 21 different solid tumor types. The highest frequency of NTRK gene fusions in patients by cancer type was head and neck cancer (22/1678, 1.31%) and thyroid cancer (7/534, 1.31%), followed by soft tissue sarcoma (STS) (19/2077, 0.91%). NTRK gene fusions were identified in several rare cancer types, including testis cancer (1/84), giving a prevalence of 1.19%. Identification of NTRK gene fusions in solid tumors with CGP testing enables an accurate diagnosis and TRK inhibitor treatment as a potential therapeutic option. Background Members of the neurotrophic tropomyosin receptor kinase (NTRK) gene family, NTRK1, NTRK2, and NTRK3 encode TRK receptor tyrosine kinases. Intra‐ or inter‐chromosomal gene rearrangements produce NTRK gene fusions encoding fusion proteins which are oncogenic drivers in various solid tumors. Methods This study investigated the prevalence of NTRK fusion genes and identified fusion partners in Japanese patients with solid tumors recorded in the Center for Cancer Genomics and Advanced Therapeutics database of comprehensive genomic profiling test. Results In the analysis population (n = 46,621), NTRK fusion genes were detected in 91 patients (0.20%). The rate was higher in pediatric cases (<18 years; 1.69%) than in adults (0.16%). NTRK gene fusions were identified in 21 different solid tumor types involving 38 different partner genes including 22 (57.9%) previously unreported NTRK gene fusions. The highest frequency of NTRK gene fusions was head and neck cancer (1.31%) and thyroid cancer (1.31%), followed by soft tissue sarcoma (STS; 0.91%). A total of 97 NTRK fusion gene partners were analyzed involving mainly NTRK1 (49.5%) or NTRK3 (44.2%) gene fusions. The only fusion gene detected in head and neck cancer was ETV6::NTRK3 (n = 22); in STS, ETV6::NTRK3 (n = 7) and LMNA::NTRK1 (n = 5) were common. Statistically significant mutual exclusivity of NTRK fusions with alterations was confirmed in TP53, KRAS, and APC. NTRK gene fusion was detected from 11 STS cases: seven unclassified sarcoma, three sarcoma NOS, and one Ewing sarcoma. Conclusions NTRK gene fusion identification in solid tumors enables accurate diagnosis and potential TRK inhibitor therapy.

oncology